NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway

Launched by UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST · Nov 1, 2024

Keywords

ClinConnect Summary

The NEWPROMRI-PATHWAY trial is exploring a new way to use magnetic resonance imaging (MRI) for diagnosing and managing prostate cancer. Prostate cancer is a common illness among men, and the need for MRI scans is increasing. However, there aren’t enough radiologists—doctors who read these scans—available to handle the growing demand. This situation can lead to delays in care and may require patients to undergo unnecessary procedures. The trial aims to improve this process by training experienced MRI radiographers (the professionals who perform the scans) to make decisions about prostate MRIs, supported by a computer system. This could potentially enhance how quickly and effectively patients are diagnosed and treated.

To participate in this trial, MRI radiographers from specific hospitals must have over five years of experience with prostate MRIs and complete specialized training. The study will also review data from 800 patients who have undergone these scans and subsequent biopsies. While the trial is not yet recruiting participants, it holds promise for improving prostate cancer care by streamlining the MRI process and making better use of available resources.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • MRI radiographers in University Hospitals of North Midlands (UHNM) and or University Hospitals of Derby and Burton (UHDB) with over 5 years' experience in MRI of the prostate.
• • Radiographers from UHNM or UHDB who have completed an online and hands on study specific training materials before the testing phase.
• • Retrospective data of 800 patients each from UHNM and UHDB who have had mpMRI and went on to have a biopsy.
• Exclusion Criteria:
• • Non-MRI radiographers.
• • Radiographers who did not completed an online and hands on study specific training materials before the testing phase.
• • Non-mpMRI.